This study aimed to compare the pharmacokinetics and tissue distribution of aerosolized pegylated interferon α-2b (PEG IFNα-2b) with standard interferon α-2b (IFNα-2b) in an animal model, paving the way for further investigation into their pharmacodynamics.
Methods:
Fifty-six Sprague Dawley rats were divided into 14 groups receiving either PEG IFNα-2b or standard IFNα-2b via aerosolized inhalation into the lower respiratory tract. Each group received a single dose of consistent concentration and volume. Pharmacokinetic parameters such as Cmax, Tmax, t1/2, AUC(0-t), and MRT(0-t) were evaluated through blood samples and tissue dissection at specified time intervals post-administration.
Results:
Analysis revealed significantly higher AUC(0-t) and MRT(0-t) in the lungs, trachea, and bronchi of the PEG IFNα-2b group compared to the standard IFNα-2b group (p < 0.05), with minimal systemic exposure.
Conclusion:
Aerosolized PEG IFNα-2b demonstrated increased drug exposure and retention in the lower respiratory tract compared to standard IFNα-2b, suggesting potential therapeutic advantages such as reduced dosing frequency. Further studies are warranted to explore enhanced clinical outcomes.
LanaspaM, BassatQ, MedeirosMM, et al.Respiratory microbiota and lower respiratory tract disease. Expert Rev Anti Infect Ther, 2017; 15(7):703–711; doi: 10.1080/14787210.2017.1349609
2.
YangC, LiuJ, ChuL. Pharmacokinetics and tissue distribution of interferon α2b (Pseudomonas putida) administered via atomization inhalation and intramuscular injection by 125 I labeling. Int J Radiat Med Nucl Med., 2015; 39(3):191–196.
3.
Chinese Society of Clinical Pharmacy <Expert consensus on rational use of nebulized inhalation therapy> writing group, Expert consensus on rational use of nebulized inhalation therapy (2019). Herald of Medicine, 2019; 38(2):135–146.
4.
Chinese Society of Thoracic Society «Expert consensus on the application of nebulized inhalation therapy in respiratory diseases» expert group. Expert consensus on the application of nebulized inhalation therapy in respiratory diseases. National Med J China, 2016; 96(34):2696–2708.
5.
DhandR. Inhaled drug therapy 2016: The year in review. Respir Care, 2017; 62(7):978–996; doi: 10.4187/respcare.05624
6.
de WeerdNA, NguyenT. The interferons and their receptors–distribution and regulation. Immunol Cell Biol, 2012; 90(5):483–491; doi: 10.1038/icb.2012.9
7.
JiangR, HanB, SongM, et al.Efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial. J Inflamm (Lond), 2020; 17:19; doi: 10.1186/s12950-020-00249-1
8.
LiuJ, LiuJ, ChuL, et al.Biodistribution and metabolic pathway of Interferon-α1b administered by aerosol inhalation in rabbits. Herald of Medicine, 2013; 31(1):1–5.
9.
GiosuèS, CasariniM, AmeglioF, et al.Minimal dose of aerosolized interferon-alpha in human subjects: Biological consequences and side-effects. Eur Respir J, 1996; 9(1):42–46; doi: 10.1183/09031936.96.09010042
10.
DiazKT, SkariaS, HarrisK, et al.Delivery and safety of inhaled interferon-γ in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv, 2012; 25(2):79–87; doi: 10.1089/jamp.2011.0919
11.
HalmeM, MaasiltaP, RepoH, et al.Inhaled recombinant interferon gamma in patients with lung cancer: Pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages and peripheral blood neutrophils and monocytes. Int J Radiat Oncol Biol Phys, 1995; 31(1):93–101; doi: 10.1016/0360-3016(94)00365-r
12.
MonkPD, MarsdenRJ, TearVJ, Inhaled Interferon Beta COVID-19 Study Group. et al.; Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med, 2021; 9(2):196–206; doi: 10.1016/s2213-2600(20)30511-7
13.
IvashkivLB, DonlinLT. Regulation of type I interferon responses. Nat Rev Immunol, 2014; 14(1):36–49; doi: 10.1038/nri3581
14.
McLeodVM, ChanLJ, RyanGM, et al.Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration. J Pharm Sci, 2015; 104(4):1421–1430; doi: 10.1002/jps.24353
15.
DunnGP, KoebelCM, SchreiberRD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol, 2006; 6(11):836–848; doi: 10.1038/nri1961
16.
SmaldoneGC. Repurposing of gamma interferon via inhalation delivery. Adv Drug Deliv Rev, 2018; 133:87–92; doi: 10.1016/j.addr.2018.06.004
17.
GiosuèS, CasariniM, AmeglioF, et al.Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur Cytokine Netw, 2000; 11(1):99–104.
18.
GiosuéS, CasariniM, AlemannoL, et al.Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am J Respir Crit Care Med, 1998; 158(4):1156–1162; doi: 10.1164/ajrccm.158.4.9803065
19.
MillerCH, MaherSG, YoungHA. Clinical use of interferon-gamma. Annals New York Acad Sci, 2009; 1182(1):69–79; doi: 10.1111/j.1749-6632.2009.05069.x
20.
DepreterF, PilcerG, AmighiK. Inhaled proteins: Challenges and perspectives. Int J Pharm, 2013; 447(1–2):251–280; doi: 10.1016/j.ijpharm.2013.02.031
21.
SnellNJ. New treatments for viral respiratory tract infections–opportunities and problems. J Antimicrob Chemother, 2001; 47(3):251–259; doi: 10.1093/jac/47.3.251
22.
HeL, YangL, ZhangH, et al.Efficacy and safety of interferon on neonates with respiratory syncytial virus pneumonia. Exp Ther Med, 2020; 20(6):220; doi: 10.3892/etm.2020.9350
23.
GereinV, RastorguevE, GereinJ, et al.Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann Otol Rhinol Laryngol, 2005; 114(6):463–471; doi: 10.1177/000348940511400608
24.
HuangX, ZhangX, WangF, et al.Clinical efficacy of therapy with recombinant human interferon α1b in hand, foot, and mouth disease with enterovirus 71 infection. PLoS One, 2016; 11(2):e0148907; doi: 10.1371/journal.pone.0148907
25.
ChannappanavarR, FehrAR, ZhengJ, et al.IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest, 2019; 129(9):3625–3639; doi: 10.1172/jci126363
26.
YuJ, LuX, TongL, et al.Interferon-α-2b aerosol inhalation is associated with improved clinical outcomes in patients with coronavirus disease-2019. Br J Clin Pharmacol, 2021; 87(12):4737–4746; doi: 10.1111/bcp.14898
27.
ShenK, ZhangG, ShangX. Expert consensus on the clinical application of recombinant human interferon-α1b in pediatrics. Chin J Appl Clin Pediatr, 2015; 30(16):1214–1219.
28.
ShenK, QianY, XuW. Expert consensus on the diagnosis, treatment, and prevention of respiratory syncytial virus infection in children. Chin J Appl Clin Pediatr, 2020; 35(4):241–250.
29.
YuH, LiXW, LiuQB, et al.Diagnosis and treatment of herpangina: Chinese expert consensus. World J Pediatr, 2020; 16(2):129–134; doi: 10.1007/s12519-019-00277-9
30.
AlhazzaniW, MøllerMH, ArabiYM, et al.Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med, 2020; 46(5):854–887; doi: 10.1007/s00134-020-06022-5
31.
HarrisJM, MartinNE, ModiM. Pegylation: A novel process for modifying pharmacokinetics. Clin Pharmacokinet, 2001; 40(7):539–551; doi: 10.2165/00003088-200140070-00005
32.
DavarD, WangH, ChauvinJM, et al.Phase Ib/II study of pembrolizumab and pegylated-interferon Alfa-2b in advanced melanoma. J Clin Oncol, 2018; 36(35):Jco1800632; doi: 10.1200/jco.18.00632
33.
KasaiK, UshioA, KasaiY, et al.Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. Cancer, 2012; 118(13):3302–3310; doi: 10.1002/cncr.26648
34.
ZhaoH, KurbanovF, WanMB, et al.Genotype B and younger patient age associated with better response to low-dose therapy: A trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis, 2007; 44(4):541–548; doi: 10.1086/511042
35.
LiWC, WangMR, KongLB, et al.Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: A meta-analysis of controlled clinical trials. BMC Infect Dis, 2011; 11(1):165; doi: 10.1186/1471-2334-11-165
36.
CooksleyWG, PiratvisuthT, LeeSD, et al.Peginterferon alpha-2a (40 kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat, 2003; 10(4):298–305; doi: 10.1046/j.1365-2893.2003.00450.x
37.
LiuS, ZhengH, HuangY, et al.The effect of peginterferon alpha-2a vs. interferon alpha-2a on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients. Clin Res Hepatol Gastroenterol, 2016; 40(3):304–308; doi: 10.1016/j.clinre.2015.06.023
YangB. Integration of Pharmacokinetics and Pharmacodynamics into the Drug Development of Pegfilgrastim, a Pegylated Protein. Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany; 2006.
40.
ZeuzemS, FeinmanSV, RasenackJ, et al.Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med, 2000; 343(23):1666–1672; doi: 10.1056/nejm200012073432301
41.
MuralidharanP, MalloryE, MalapitM, et al.Inhalable pegylated phospholipid nanocarriers and pegylated therapeutics for respiratory delivery as aerosolized colloidal dispersions and dry powder inhalers[J]. Pharmaceutics, 2014; 6(2):333–353; doi: 10.3390/pharmaceutics6020333
42.
KaminskasLM, McLeodVM, RyanGM, et al.Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy[J]. J Control Release, 2014; 183:18–26; doi: 10.1016/j.jconrel.2014.03.012
43.
RyanGM, KaminskasLM, KellyBD, et al.Pulmonary administration of pegylated polylysine dendrimers: Absorption from the lung versus retention within the lung is highly size-dependent[J]. Mol Pharm, 2013; 10(8):2986–2995; doi: 10.1021/mp400091n
44.
GursahaniH, Riggs-SauthierJ, PfeifferJ, et al.Absorption of polyethylene glycol (peg) polymers: The effect of peg size on permeability[J]. J Pharm Sci, 2009; 98(8):2847–2856; doi: 10.1002/jps.21635
